Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients
- Sponsor
- Weizmann Institute of Science
- Study ID
- NCT07648433
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Myeloproliferative Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- PERIBLOOD-MPN — DIAGNOSTIC_TESTObservational intervation of cHSPCs
Study Details
The PERIBLOOD-MPN study aims to develop and validate a minimally invasive peripheral blood test using single-cell RNA sequencing to accurately diagnose and classify myeloproliferative neoplasms, potentially reducing the need for invasive bone marrow biopsies.
Key Dates
- First listed
- Jun 15, 2026
- Start date
- Oct 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2032
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
To development PERIBLOOD-MPN Diagnostic Test [ Time Frame: Three months following the PB sample ]
Central Contacts
- Liran Shlush, Prof.+97289342247
- Gil Gonen Yaacovi, PhD+9728747027401
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Boston, Massachusetts
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas